Viemed Healthcare US (VMD) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Viemed Healthcare reports a triumphant financial year for 2023, achieving record net revenues of $183 million and a net income increase of 65%, marking its seventh consecutive year of growth. The company also celebrated a significant surge in free cash flow and concluded the year with a strong balance sheet, despite taking on some long-term debt from a substantial acquisition. Looking ahead, Viemed anticipates revenues up to $51 million in the first quarter of 2024, independent of Medicare reimbursement rate adjustments.
For further insights into VMD stock, check out TipRanks’ Stock Analysis page.
